Adrian Gillissen1, Peter Haidl, Martin Khlhäufl, Klaus Kroegel, Thomas Voshaar, Christian Gessner. 1. Department of Pulmonary Medicine, Kassel General Hospital, Fachkrankenhaus Kloster Grafschaft, Schmallenberg, Klinik Schillerhöhe, Stuttgart, Department of Internal Medicine I: Pneumology & Allergology/Immunology, Friedrich Schiller University Jena, Department of Pneumology and Allergy, Medical Clinic III, Bethanien Hospital Moers, Department of Pneumology, University of Leipzig.
Abstract
BACKGROUND: Inhaled corticosteroids (ICS) are markedly less effective against chronic obstructive pulmonary disease (COPD) than against asthma, and also have worse side effects. Whether ICS should be used to treat COPD is currently a matter of debate. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed and the Excerpta Medica Database (EMBASE) carried out in May 2015. We analyzed clinical trials of ICS for the treatment of COPD with a duration of at least one year, along with meta-analyses and COPD guidelines. RESULTS: ICS lower the frequency and severity of COPD exacerbations in comparison to monotherapy with a long-acting ß2-agonist, but have no effect on mortality. Compared to placebo, ICS monotherapy lessens the decline of forced expiratory volume in one second (FEV1) over one year by merely 5.80 mL (statistically insignificant; 95% confidence interval: [-0.28; 11.88]) and only marginally improve quality of life. ICS use in patients with COPD increases the risk of pneumonia. A combination of ICS with a long-acting bronchodilator improves FEV1 by 133 mL [105; 161] and lowers the frequency of severe exacerbations by 39% . The frequency of exacerbations is lowered mainly in patients who have many exacerbations; thus, ICS treatment is suitable only for patients with grade III or IV COPD. CONCLUSION: ICS monotherapy has no clinically useful effect on pulmonary function in COPD. The main form of drug treatment for COPD is with broncho - dilators, either alone or in combination with ICS. ICS can be given to patients with grade III or IV COPD to make exacerbations less frequent. Patients with an asthma-COPD overlap syndrome (ACOS) can benefit from ICS treatment.
BACKGROUND: Inhaled corticosteroids (ICS) are markedly less effective against chronic obstructive pulmonary disease (COPD) than against asthma, and also have worse side effects. Whether ICS should be used to treat COPD is currently a matter of debate. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed and the Excerpta Medica Database (EMBASE) carried out in May 2015. We analyzed clinical trials of ICS for the treatment of COPD with a duration of at least one year, along with meta-analyses and COPD guidelines. RESULTS:ICS lower the frequency and severity of COPD exacerbations in comparison to monotherapy with a long-acting ß2-agonist, but have no effect on mortality. Compared to placebo, ICS monotherapy lessens the decline of forced expiratory volume in one second (FEV1) over one year by merely 5.80 mL (statistically insignificant; 95% confidence interval: [-0.28; 11.88]) and only marginally improve quality of life. ICS use in patients with COPD increases the risk of pneumonia. A combination of ICS with a long-acting bronchodilator improves FEV1 by 133 mL [105; 161] and lowers the frequency of severe exacerbations by 39% . The frequency of exacerbations is lowered mainly in patients who have many exacerbations; thus, ICS treatment is suitable only for patients with grade III or IV COPD. CONCLUSION:ICS monotherapy has no clinically useful effect on pulmonary function in COPD. The main form of drug treatment for COPD is with broncho - dilators, either alone or in combination with ICS. ICS can be given to patients with grade III or IV COPD to make exacerbations less frequent. Patients with an asthma-COPD overlap syndrome (ACOS) can benefit from ICS treatment.
Authors: Donald A Mahler; Patrick Wire; Donald Horstman; Chai-Ni Chang; Julie Yates; Tracy Fischer; Tushar Shah Journal: Am J Respir Crit Care Med Date: 2002-10-15 Impact factor: 21.405
Authors: W Szafranski; A Cukier; A Ramirez; G Menga; R Sansores; S Nahabedian; S Peterson; H Olsson Journal: Eur Respir J Date: 2003-01 Impact factor: 16.671
Authors: Helgo Magnussen; Bernd Disse; Roberto Rodriguez-Roisin; Anne Kirsten; Henrik Watz; Kay Tetzlaff; Lesley Towse; Helen Finnigan; Ronald Dahl; Marc Decramer; Pascal Chanez; Emiel F M Wouters; Peter M A Calverley Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245
Authors: Stephen I Rennard; Donald P Tashkin; Jennifer McElhattan; Mitchell Goldman; Sulabha Ramachandran; Ubaldo J Martin; Philip E Silkoff Journal: Drugs Date: 2009 Impact factor: 9.546
Authors: R A Bontsevich; A V Adonina; Y R Vovk; G A Batisheva; O V Cherenkova; G G Ketova; V O Barysheva; E V Luchinina; T G Pokrovskaia Journal: Arch Razi Inst Date: 2022-02-28